Ernexa Therapeutics (NASDAQ:ERNA) Upgraded at Zacks Research

Ernexa Therapeutics (NASDAQ:ERNA) was upgraded by stock analysts at Zacks Research to a “hold” rating in a report issued on Monday,Zacks.com reports.

A number of other equities research analysts also recently weighed in on ERNA. Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Tuesday, April 21st. Brookline Capital Markets assumed coverage on Ernexa Therapeutics in a report on Thursday, May 7th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Wall Street Zen raised Ernexa Therapeutics to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $30.00.

Ernexa Therapeutics Price Performance

Shares of ERNA stock opened at $12.01 on Monday. Ernexa Therapeutics has a one year low of $3.18 and a one year high of $100.46. The firm has a market cap of $14.00 million, a price-to-earnings ratio of -0.46 and a beta of 1.88. The stock’s fifty day simple moving average is $5.99 and its 200 day simple moving average is $20.68.

Ernexa Therapeutics (NASDAQ:ERNA) last released its quarterly earnings results on Monday, May 11th. The company reported ($6.95) earnings per share (EPS) for the quarter. On average, research analysts anticipate that Ernexa Therapeutics will post -9.38 earnings per share for the current year.

Hedge Funds Weigh In On Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent quarter. 70.55% of the stock is currently owned by institutional investors.

Key Ernexa Therapeutics News

Here are the key news stories impacting Ernexa Therapeutics this week:

• Positive Sentiment: Brookline Capital Markets reiterated a Buy rating on Ernexa Therapeutics and maintained a $30 price target, while also publishing multi-year EPS estimates that suggest continued analyst attention on the name. Brookline Capital Markets earnings estimates
• Positive Sentiment: The company also released a virtual investor KOL Connect segment focused on the ovarian cancer market and its lead candidate ERNA-101, which may be supporting speculative interest in the stock. Investor KOL Connect segment
• Neutral Sentiment: Ernexa reported quarterly EPS of ($6.95), which was far worse than analyst expectations of ($1.95). That is fundamentally negative, but the market appears to be focusing more on trading momentum and analyst optimism than on the earnings miss. Earnings results
• Neutral Sentiment: ERNA was repeatedly placed on LULD pause halts during the morning session, indicating extreme volatility and heavy trading rather than a single new fundamental development. Trading halts
• Negative Sentiment: The earnings report showed a large miss versus consensus, which would normally pressure the stock and highlights the company’s still-significant losses. Earnings miss

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.